GRYFN turns data collection chaos into clarity, helping researchers focus on what mattersBy automating labor intensive data gathering and processing, GRYFN technology augments rather than replaces human talent, automating manual tasks and enabling deeper, faster insights.
Amplified Sciences earns CLIA certification for its first test to assess pancreatic cancer riskCompany to commercialize PanCystPro, including establishing an early access program and completing a clinical utility trial in 2025
Purdue innovations detect lead exposure faster, easier and with greater precision at the point of careNew patent-pending methods use portable XRF analyzers to test bone for chronic exposure and dried blood spots for recent exposure
Emboa Medical creates, validates novel catheter to improve stroke patients’ outcomesMedical device startup licenses Purdue University TRAP design that mimics boa constrictor teeth
High-tech startup CrySyst provides quality-by-control solutions for pharmaceutical, fine chemical industriesInnovative crystallization monitoring, modeling and control software solutions address process development challenges
Biotech company Eradivir is developing lead drug EV25 to treat influenzaCompany has completed the required preclinical studies and will seek regulatory approval to dose volunteers in Belgium by the end of the year
Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a study of influenza therapeuticWEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The funding will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.CEO Martin Low said EV25 consistently outperforms the current standard of care for influenza in preclinical models.“Within 24 hours of taking EV25, the amount of live virus present in preclinical models was reduced to nondetectable amounts,” he said. “The Phase 2a and Phase 2b trials will collectively demonstrate EV25’s safety and efficacy in humans, starting with proof of concept and culminating in a real-world setting.”EV25 was built on a platform created by Philip Low, the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in Purdue University’s College of Science. Low is part of Purdue’s One Health initiative, which advances the university strengths in human, animal, plant and environmental health. He also is on the faculty of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research. Philip Low is Eradivir’s chief scientific officer and on its board of directors.Philip Low disclosed the immunological innovations to the Purdue Innovates Office of Technology Commercialization, which has applied for patents to protect the intellectual property. OTC licensed the innovations to Eradivir for further development and commercialization.
From eureka moments to industry impact: Tillmann Kubis’ quantum code libraryWhat drives a researcher’s decades-spanning dedication to changing the world? For Kubis, it’s an integral drive to preserve knowledge and solve the fundamental problems people experience.
34 Lives has saved 10 lives with “unusable” kidneys — and they’re just getting startedEvery day in the US, approximately 34 patients are removed from the transplant waiting list either because they die or they become too sick to receive a transplant. 34 Lives aims to bring that number to zero.
Global Impact: Purdue University Airport a gateway to aviation innovationWEST LAFAYETTE, IN, May 14, 2024 (GLOBE NEWSWIRE) -- Purdue University Airport (LAF) enters a new era on May 15th as it launches the first commercial air service since 2004, offering 4 weekly round-trip flights from West Lafayette to Chicago O'Hare (ORD). In addition, construction will soon begin on the new, $11.8 million, approximately 9,400-square-foot Amelia Earhart Terminal.
SK hynix announces semiconductor advanced packaging investment in Purdue Research ParkThe company's facility for AI memory chips marks the largest single economic development in the history of the state
Purdue researcher awarded $1.3 million for malaria drug trials in Southeast Asia and AfricaPhilip Low looks to validate previous trial results and test whether the number of days of an anti-malaria drug therapy can be reduced
Boosting Brown Fat to Combat Obesity and Type 2 DiabetesTreatment in development by Adipo Therapeutics holds promise for millions who struggle with weight loss and blood glucose control
Ericsson, Saab and Purdue University announce ‘lab to life’ innovative 5G network to make Purdue Airport accessible as a real-life research site for aviation industryWEST LAFAYETTE, Ind., March 21, 2023 (GLOBE NEWSWIRE) -- WEST LAFAYETTE, Ind. – Purdue University Airport, in collaboration with industry partners Ericsson and Saab, announced Monday (March 20) the creation of a unique 5G network that will serve as a “lab to life” proving ground for academics, researchers and business to develop commercial solutions that can be replicated to improve operations and security at airports of all sizes. 5G innovation has promised to provide a new generation of capabilities for enterprises. This project aims to bring to life the benefits of private 5G for airports, where new high-performance networks can be tested in real-life scenarios.
Amplified Sciences, Inc. revolutionizing early-detection diagnostics of pancreatic cancer and other diseasesThe Purdue-affiliated startup is on a mission to deliver lifesaving diagnostics: accurately detecting and pre-empting the risks of debilitating diseases.
